Anhui Fengyuan Pharmaceutical Co Ltd - Asset Resilience Ratio
Anhui Fengyuan Pharmaceutical Co Ltd (000153) has an Asset Resilience Ratio of 1.81% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 000153 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2020)
This chart shows how Anhui Fengyuan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 000153 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Anhui Fengyuan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 000153 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥80.69 Million | 1.81% |
| Total Liquid Assets | CN¥80.69 Million | 1.81% |
Asset Resilience Insights
- Limited Liquidity: Anhui Fengyuan Pharmaceutical Co Ltd maintains only 1.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Anhui Fengyuan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Anhui Fengyuan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Anhui Fengyuan Pharmaceutical Co Ltd (2016–2020)
The table below shows the annual Asset Resilience Ratio data for Anhui Fengyuan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.19% | CN¥6.99 Million ≈ $1.02 Million |
CN¥3.64 Billion ≈ $532.09 Million |
-0.09pp |
| 2019-12-31 | 0.28% | CN¥9.87 Million ≈ $1.44 Million |
CN¥3.56 Billion ≈ $520.88 Million |
+0.02pp |
| 2018-12-31 | 0.26% | CN¥7.79 Million ≈ $1.14 Million |
CN¥3.01 Billion ≈ $440.16 Million |
-0.23pp |
| 2017-12-31 | 0.49% | CN¥13.47 Million ≈ $1.97 Million |
CN¥2.77 Billion ≈ $405.00 Million |
-0.32pp |
| 2016-12-31 | 0.81% | CN¥20.06 Million ≈ $2.94 Million |
CN¥2.49 Billion ≈ $364.42 Million |
-- |
About Anhui Fengyuan Pharmaceutical Co Ltd
Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells medicines in China. The company also exports its products. Anhui Fengyuan Pharmaceutical Co., Ltd. was incorporated in 1997 and is based in Hefei, China.